Rapid reduction of σ1-receptor binding and 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin

Journal of Nuclear Medicine

Volumn 48, Issue 8, 2007, Pages 1320-1326

  Van Waarde, Aren ^a   Shiba, Kazuhiro ^b   De Jong, Johan R ^a   Ishiwata, Kiichi ^c   Dierckx, Rudi A ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b KANAZAWA UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

11C SA4503; Chemotherapy; Doxorubicin; MicroPET; Tumor

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE C 11; CARBON 11; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; LIGAND; PENTOBARBITAL; SIGMA 1 OPIATE RECEPTOR; SODIUM CHLORIDE; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CARBON; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA1 BINDING PROTEIN, RAT; SIGMA1-BINDING PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DISTRIBUTION; GENE OVEREXPRESSION; GLIOMA; HOMOGENATE; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; TUMOR GROWTH; WEIGHT GAIN; ANIMAL; METABOLISM; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARBON RADIOISOTOPES; DOXORUBICIN; FLUORODEOXYGLUCOSE F18; GLIOMA; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, WISTAR; RECEPTORS, SIGMA; TISSUE DISTRIBUTION;

EID: 34547748903     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.042085     Document Type: Article

References (30)

1. Bem WT, Thomas GE, Mamone JY, et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 1991;51:6558-6562.
2. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55: 408-413.
3. Aydar E, Onganer P, Perrett R, Djamgoz MB. Palmer CP. The expression and functional characterization of sigma-1 receptors in breast cancer cell lines. Cancer Lett. 2006;242:245-257.
4. Azzariti A, Colabufo NA, Berardi F, et al. Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigmal antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol Cancer Ther. 2006;5:1807-1816.
5. Colabufo NA, Berardi F, Contino M, et al. Antiproliferative and cytotoxic effects of some sigma2 agonists and sigmal antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:106-113.
6. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64: 4875-4886.
7. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002;62:313-322.
8. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005;65:8975-8983.
9. Bowen WD. Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv. 2000;74:211-218.
10. Al Nabulsi I, Mach RH, Wang LM, et al. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer. 1999;81:925-933.
11. Wheeler KT, Wang LM, Wallen CA, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer. 2000;82:1223-1232.
12. Simony-Lafontaine J, Esslimani M, Bribes E, et al. Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer. 2000;82:1958-1966.
13. Van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006;47:150-154.
14. Van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH. Early response of sigrna-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med. 2006;47:1538-1545.
15. 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]- 4-(3-phenylpropyl) piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol. 2003;30:273-284.
16. 11C-SA4503: a feasibility study. J Nucl Med. 2004;45:1939-1945.
17. 18F]FDG in the liver metastasis rat model. Ann Nucl Med. 2006;20:463-469.
18. Lui RC, Laregina MC, Herbold DR, Johnson FE. Testicular cytotoxicity of intravenous doxorubicin in rats. J Urol. 1986;136:940-943.
19. Gosalvez M, Blanco MF, Vivero C, Valles F. Quelamycin, a new derivative of adriamycin with several possible therapeutic advantages. Eur J Cancer. 1978; 14: 1185-1190.
20. Olson F, Mayhew E, Maslow D, Rustum Y, Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol. 1982;18:167-176.
21. Yeung TK, Simmonds RH, Hopewell JW. A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat. Radiother Oncol. 1989; 15:275-284.
22. 11C]SA4503 for imaging of sigma receptors in tumors by animal PET. Ann Nucl Med. 2005;19:701-709.
23. John CS, Bowen WD, Saga T, et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med. 1993;34:2169-2175.
24. Durand RE, LePard NE. Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother Oncol. 1997;42:171-179.
25. Denis F, Colas S, Chami L, et al. Changes in tumor vascularization after irradiation, anthracyclin, or antiangiogenic treatment in nitrosomethyl ureas-induced rat mammary tumors. Clin Cancer Res. 2003;9:4546-4552.
26. Amoh Y, Li L, Yang M, et al. Hair follicle-derived blood vessels vascularize tumors in skin and are inhibited by doxorubicin. Cancer Res. 2005;65:2337-2343.
27. Spaepen K, Stroobants S, Dupont P, et al. [F-18]FDG PET monitoring of tumour response to chemotherapy: does [F-18]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30: 682-688.
28. Takeda N, Diksic M, Yamamoto YL. The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. Cancer. 1996;77:1167-1179.
29. Burholt DR, Hagemann RF, Schenken LL, Lesher S. Influence of adriamycin and adriamycin-radiation combination on jejunal proliferation in the mouse. Cancer Res. 1977;37:22-27.
30. Buts JP, De Meyer R, Van Craynest MP, Maldague P. Adaptive response of growing rat small intestine to acute adriamycin injury. J Pediatr Gastroenterol Nutr. 1983;2:159-165.